Literature DB >> 15694368

AICAR, an activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells.

Kazuhiko Nakamaru1, Kazuya Matsumoto, Tetsuya Taguchi, Mihoshi Suefuji, Yusuke Murata, Motoyuki Igata, Junji Kawashima, Tatsuya Kondo, Hiroyuki Motoshima, Kaku Tsuruzoe, Nobuhiro Miyamura, Tetsushi Toyonaga, Eiichi Araki.   

Abstract

The liver is one of the major target organs of insulin in which the expression of insulin receptor is abundant. We analyzed the effect of AICAR, an AMPK activator, on the expression of insulin receptor in a human hepatoma cell line, HepG2 cells. AICAR treatment for 48 h significantly decreased the expression of the insulin receptor protein in a dose-dependent manner, however, this same effect of AICAR was not observed in either 3T3-L1 adipocytes or CHO cells. The expression of insulin receptor mRNA also decreased after AICAR treatment. In addition, the transcriptional activity of the insulin receptor gene promoter investigated with a luciferase assay was down-regulated by AICAR treatment. Dipyridamole, an adenosine transporter inhibitor, and 5'-amino-5'-deoxyadenosine, an adenosine kinase inhibitor, blocked the effect of AICAR on the down-regulation of the insulin receptor protein, mRNA, and promoter activity. Our findings suggest, for the first time, that AMPK activation could reduce the expression of insulin receptor, at least in part, by a down-regulation of the transcriptional level, and this effect may be liver specific.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694368     DOI: 10.1016/j.bbrc.2005.01.004

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Metabolomics and proteomics identify the toxic form and the associated cellular binding targets of the anti-proliferative drug AICAR.

Authors:  Delphine C Douillet; Benoît Pinson; Johanna Ceschin; Hans C Hürlimann; Christelle Saint-Marc; Damien Laporte; Stéphane Claverol; Manfred Konrad; Marc Bonneu; Bertrand Daignan-Fornier
Journal:  J Biol Chem       Date:  2018-11-26       Impact factor: 5.157

2.  The last enzyme of the de novo purine synthesis pathway 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) plays a central role in insulin signaling and the Golgi/endosomes protein network.

Authors:  Martial Boutchueng-Djidjou; Gabriel Collard-Simard; Suzanne Fortier; Sébastien S Hébert; Isabelle Kelly; Christian R Landry; Robert L Faure
Journal:  Mol Cell Proteomics       Date:  2015-02-16       Impact factor: 5.911

3.  Metformin Attenuates Aβ Pathology Mediated Through Levamisole Sensitive Nicotinic Acetylcholine Receptors in a C. elegans Model of Alzheimer's Disease.

Authors:  Waqar Ahmad; Paul R Ebert
Journal:  Mol Neurobiol       Date:  2016-09-05       Impact factor: 5.590

4.  Suppression of adipose lipolysis by long-chain fatty acid analogs.

Authors:  Bella Kalderon; Narmen Azazmeh; Nili Azulay; Noam Vissler; Michael Valitsky; Jacob Bar-Tana
Journal:  J Lipid Res       Date:  2012-02-14       Impact factor: 5.922

5.  Diverse cytopathologies in mitochondrial disease are caused by AMP-activated protein kinase signaling.

Authors:  Paul B Bokko; Lisa Francione; Esther Bandala-Sanchez; Afsar U Ahmed; Sarah J Annesley; Xiuli Huang; Taruna Khurana; Alan R Kimmel; Paul R Fisher
Journal:  Mol Biol Cell       Date:  2007-03-01       Impact factor: 4.138

Review 6.  Nuclear receptors and AMPK: can exercise mimetics cure diabetes?

Authors:  Christopher E Wall; Ruth T Yu; Anne R Atkins; Michael Downes; Ronald M Evans
Journal:  J Mol Endocrinol       Date:  2016-04-22       Impact factor: 5.098

7.  Identification of yeast and human 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAr) transporters.

Authors:  Johanna Ceschin; Christelle Saint-Marc; Jean Laporte; Adrien Labriet; Chloé Philippe; Michel Moenner; Bertrand Daignan-Fornier; Benoît Pinson
Journal:  J Biol Chem       Date:  2014-04-28       Impact factor: 5.157

8.  Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells.

Authors:  Zhaofan Luo; Ying Zhang; Fangping Li; Juan He; Helin Ding; Li Yan; Hua Cheng
Journal:  Endocrine       Date:  2009-05-08       Impact factor: 3.633

9.  AMP activated kinase negatively regulates hepatic Fetuin-A via p38 MAPK-C/EBPβ/E3 Ubiquitin Ligase Signaling pathway.

Authors:  Vishal Kothari; Jeganathan Ramesh Babu; Suresh T Mathews
Journal:  PLoS One       Date:  2022-05-06       Impact factor: 3.240

10.  The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome.

Authors:  Xuguang Hu; Man Wang; Weijian Bei; Zongyu Han; Jiao Guo
Journal:  J Transl Med       Date:  2014-02-20       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.